Last reviewed · How we verify
NCT06667349: TISSARA
TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk
Phase 4 trial testing Ticagrelor in STEMI - ST Elevation Myocardial Infarction in 1,727 participants. Completed in 16 June 2024.
3 March 2024
Quick facts
| Lead sponsor | National Institute of Cardiovascular Diseases, Pakistan |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,727 |
| Start date | 24 August 2023 |
| Primary completion | 3 March 2024 |
| Estimated completion | 16 June 2024 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Ticagrelor (ticagrelor) — full drug profile →
Conditions studied
- STEMI - ST Elevation Myocardial Infarction — all drugs for STEMI - ST Elevation Myocardial Infarction →
- Stent Thrombosis — all drugs for Stent Thrombosis →
- Antiplatelet Agents — all drugs for Antiplatelet Agents →
Sponsor
National Institute of Cardiovascular Diseases, Pakistan
Who can join
18 and older, any sex, with STEMI - ST Elevation Myocardial Infarction or Stent Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stent thrombosis (ST) remains a critical complication following primary percutaneous coronary intervention (PPCI) in patients with ST-elevation myocardial infarction (STEMI). At the National Institute of Cardiovascular Diseases in Karachi-recognized as the world's busiest PPCI center-reported rates of ST range from 4% to 6%. In response to this pressing issue, the health system has implemented a new two-week post-PCI regimen featuring ticagrelor, aimed at enhancing patient outcomes and reducing the risk of stent-related complications. The TISSARA Trial is designed to rigorously assess the effectiveness of this intervention on cardiovascular outcomes in STEMI patients. Between August, 2023 and March 2024, a total of 1,773 patients were enrolled in the trial, with 970 patients discharged on Tissara (Ticagrelor) (Ferozsons laboratories Ltd, Lahore, Pakistan) (TG) and 803 patients receiving clopidogrel (CG) following their primary PCI procedures. Each group was carefully monitored for a duration of three months to evaluate the incidence of stent thrombosis and other relevant cardiovascular events. The primary endpoint of this trial is the occurrence of stent thrombosis within the follow-up period, providing critical insights into the safety and efficacy of the ticagrelor regimen in this high-risk population. This comprehensive approach aims to contribute valuable data that may influence future treatment protocols and improve the standard of care for patients undergoing PCI in similar healthcare settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06667349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ticagrelor
Trials testing the same drug.
- NCT06451198 — IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome · Phase 4 · recruiting
- NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
- NCT06584812 — Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects · Phase 1 · completed
- NCT06554821 — A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy · Phase 1 · completed
- NCT06301776 — A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy · NA · recruiting
Other recruiting trials for STEMI - ST Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT07160491 — Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI · NA · recruiting
- NCT06013020 — Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus · Phase 4 · recruiting
- NCT06384846 — AI Algorithms in Prediction of ACS Based on Leukocyte Properties · recruiting
- NCT04436978 — What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? · Phase 4 · recruiting
- NCT05800951 — Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock · active not recruiting
Other National Institute of Cardiovascular Diseases, Pakistan trials
Trials by the same sponsor.
- NCT07229248 — DCB vs. DES in Young STEMI Patients: The DCB-STEMI Trial · Phase 3 · recruiting
- NCT07355452 — Comparing Outcomes Of Single Layer Versus Multilayer Leg Closure Techniques Following Great Saphenous Vein Harvesting Fo · NA · enrolling by invitation
- NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
- NCT06742567 — Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction · Phase 3 · recruiting
- NCT06318481 — TADCLOT- a Double Blind Randomized Controlled Trial · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06667349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Cardiovascular Diseases, Pakistan
- Last refreshed: 31 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06667349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing